Literature DB >> 12681515

Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres: the effect of the ethylene oxide chain configuration.

S M Moghimi1.   

Abstract

Lymphatic distribution of interstitially injected poloxamer 407-coated nanospheres (45 nm in diameter) is controlled by surface configuration of the ethylene oxide (EO) segments of the adsorbed copolymer. At low poloxamer surface coverage, EO tails spread laterally on a nanosphere surface and assume a 'flat or mushroom-like' configuration. Such entities drain rapidly from the subcutaneous site of injection into the initial lymphatic, when compared to uncoated nanospheres, and subsequently are captured by scavengers of the regional lymph nodes. In vitro experiments have also confirmed that such entities are prone to phagocytosis. When the equilibrium poloxamer concentration is at 75 microg/ml or greater the EO chains become more closely packed and project outward from the nanosphere surface. These surface-engineered nanospheres drain faster than those with EO chains in mushroom configurations into the initial lymphatic, escape clearance by lymph node macrophages, reach the systemic circulation, and remain in the blood for prolonged periods. These experiments provide a rational approach for the design and engineering of nano-vehicles for optimal lymphatic targeting and are discussed. Copyright 2003 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12681515     DOI: 10.1016/s0014-5793(03)00273-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

Review 1.  A review of poloxamer 407 pharmaceutical and pharmacological characteristics.

Authors:  Gilles Dumortier; Jean Louis Grossiord; Florence Agnely; Jean Claude Chaumeil
Journal:  Pharm Res       Date:  2006-11-11       Impact factor: 4.200

Review 2.  Design opportunities for actively targeted nanoparticle vaccines.

Authors:  Tarek M Fahmy; Stacey L Demento; Michael J Caplan; Ira Mellman; W Mark Saltzman
Journal:  Nanomedicine (Lond)       Date:  2008-06       Impact factor: 5.307

3.  Ease of synthesis, controllable sizes, and in vivo large-animal-lymph migration of polymeric nanoparticles.

Authors:  Kimberly Ann V Zubris; Onkar V Khullar; Aaron P Griset; Summer Gibbs-Strauss; John V Frangioni; Yolonda L Colson; Mark W Grinstaff
Journal:  ChemMedChem       Date:  2010-09-03       Impact factor: 3.466

Review 4.  Challenges in development of nanoparticle-based therapeutics.

Authors:  Neil Desai
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

Review 5.  Recent advances in lymphatic targeted drug delivery system for tumor metastasis.

Authors:  Xiao-Yu Zhang; Wei-Yue Lu
Journal:  Cancer Biol Med       Date:  2014-12       Impact factor: 4.248

Review 6.  Green Metallic Nanoparticles: Biosynthesis to Applications.

Authors:  Hitesh Chopra; Shabana Bibi; Inderbir Singh; Mohammad Mehedi Hasan; Muhammad Saad Khan; Qudsia Yousafi; Atif Amin Baig; Md Mominur Rahman; Fahadul Islam; Talha Bin Emran; Simona Cavalu
Journal:  Front Bioeng Biotechnol       Date:  2022-04-06

Review 7.  Nano-Based Theranostic Platforms for Breast Cancer: A Review of Latest Advancements.

Authors:  Rabia Arshad; Maria Hassan Kiani; Abbas Rahdar; Saman Sargazi; Mahmood Barani; Shirin Shojaei; Muhammad Bilal; Deepak Kumar; Sadanand Pandey
Journal:  Bioengineering (Basel)       Date:  2022-07-15

8.  Anaphylaxis and allergic reactions to COVID-19 vaccines: A narrative review of characteristics and potential obstacles on achieving herd immunity.

Authors:  Sara Mahdiabadi; Nima Rezaei
Journal:  Health Sci Rep       Date:  2022-08-24

9.  Revolutionary impact of nanodrug delivery on neuroscience.

Authors:  Reza Khanbabaie; Mohsen Jahanshahi
Journal:  Curr Neuropharmacol       Date:  2012-12       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.